These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33627833)

  • 41. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts.
    Drobyski WR; Klein J; Flomenberg N; Pietryga D; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 2002 Feb; 99(3):806-14. PubMed ID: 11806980
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An ENU-induced splicing mutation reveals a role for Unc93b1 in early immune cell activation following influenza A H1N1 infection.
    Lafferty EI; Flaczyk A; Angers I; Homer R; d'Hennezel E; Malo D; Piccirillo CA; Vidal SM; Qureshi ST
    Genes Immun; 2014; 15(5):320-32. PubMed ID: 24848930
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program.
    Miyamoto T; Fukuda T; Nakashima M; Henzan T; Kusakabe S; Kobayashi N; Sugita J; Mori T; Kurokawa M; Mori SI
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):938-944. PubMed ID: 28219836
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
    Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
    Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.
    Bashey A; Zhang X; Sizemore CA; Manion K; Brown S; Holland HK; Morris LE; Solomon SR
    J Clin Oncol; 2013 Apr; 31(10):1310-6. PubMed ID: 23423745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent developments in HLA-haploidentical transplantations.
    Showel M; Fuchs EJ
    Best Pract Res Clin Haematol; 2015; 28(2-3):141-6. PubMed ID: 26590771
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies.
    Fefer A; Robinson N; Benyunes MC; Bensinger WI; Press O; Thompson JA; Lindgren C
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S48-53. PubMed ID: 9457394
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The diversity of KIR gene in Chinese Northern Han population and the impact of donor KIR and patient HLA genotypes on outcome following HLA-identical sibling allogeneic hematopoietic stem cell transplantation for hematological malignancy in Chinese people.
    Dou LP; Zheng H; Wang C; Liu JH; Sun JF; Jin HJ; Gao CJ; Yu L; Da WM
    Int J Hematol; 2008 May; 87(4):422-433. PubMed ID: 18347914
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies.
    Handgretinger R; Kurtzberg J; Egeler RM
    Pediatr Clin North Am; 2008 Feb; 55(1):71-96, x. PubMed ID: 18242316
    [TBL] [Abstract][Full Text] [Related]  

  • 52. UNC93B1 and nucleic acid-sensing Toll-like receptors mediate host resistance to infection with Leishmania major.
    Schamber-Reis BL; Petritus PM; Caetano BC; Martinez ER; Okuda K; Golenbock D; Scott P; Gazzinelli RT
    J Biol Chem; 2013 Mar; 288(10):7127-36. PubMed ID: 23325805
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant.
    Moyer AM; Hashmi SK; Kroning CM; Kremers WK; De Goey SR; Patnaik M; Litzow M; Gastineau DA; Hogan WJ; Jacob EK; Kreuter JD; Wakefield LL; Gandhi MJ
    Eur J Haematol; 2017 Sep; 99(3):275-282. PubMed ID: 28632323
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
    Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
    Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.
    Munchel AT; Kasamon YL; Fuchs EJ
    Best Pract Res Clin Haematol; 2011 Sep; 24(3):359-68. PubMed ID: 21925089
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
    Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A
    Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy.
    Anandi P; Tian X; Ito S; Muranski P; Chokshi PD; Watters N; Chawla U; Hensel N; Stroncek DF; Battiwalla M; Barrett AJ
    Cytotherapy; 2017 Jun; 19(6):735-743. PubMed ID: 28395942
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel disease-associated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation.
    Nguyen Y; Al-Lehibi A; Gorbe E; Li E; Haagenson M; Wang T; Spellman S; Lee SJ; Davidson NO
    Blood; 2010 Apr; 115(17):3625-31. PubMed ID: 20177049
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation.
    van der Straaten HM; Paquay MM; Tilanus MG; van Geloven N; Verdonck LF; Huisman C
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1231-6. PubMed ID: 21215810
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.
    Brunstein CG; Fuchs EJ; Carter SL; Karanes C; Costa LJ; Wu J; Devine SM; Wingard JR; Aljitawi OS; Cutler CS; Jagasia MH; Ballen KK; Eapen M; O'Donnell PV;
    Blood; 2011 Jul; 118(2):282-8. PubMed ID: 21527516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.